Back to Search Start Over

Re-induction with venetoclax combinations or IDH inhibitors result in similar remission rates and lower treatment related morbidity among AML patients initially receiving intensive induction chemotherapy.

Authors :
Taylor S
Murthy GSG
Runaas L
Michaelis LC
Carlson K
Atallah EL
Abedin SM
Source :
Leukemia research [Leuk Res] 2023 Sep; Vol. 132, pp. 107348. Date of Electronic Publication: 2023 Jun 28.
Publication Year :
2023

Abstract

Competing Interests: Declaration of Competing Interest None.

Details

Language :
English
ISSN :
1873-5835
Volume :
132
Database :
MEDLINE
Journal :
Leukemia research
Publication Type :
Editorial & Opinion
Accession number :
37423073
Full Text :
https://doi.org/10.1016/j.leukres.2023.107348